New test may predict lung cancer treatment success

NCT ID NCT04589013

Completed Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patients before treatment and tracked disease progression or death over one year. The goal was to see if this multiparametric test outperforms the standard PD-L1 test alone in predicting outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this test could help doctors identify which lung cancer patients are most likely to benefit from immunotherapy combined with chemotherapy, avoiding ineffective treatments.
What could go wrong: This is a small, completed study that only looked at predicting outcomes, not changing treatment. The test may not be accurate enough for routine use and needs further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CH Victor Provot

Roubaix, France
Clcc Oscar Lambret Lille

Lille, 59037, France
Clinique Teissier

Valenciennes, France
Hop Calmette Chu Lille

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.